LMR Partners LLP purchased a new stake in Loxo Oncology, Inc. (NASDAQ:LOXO) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 59,551 shares of the biopharmaceutical company’s stock, valued at approximately $4,775,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp raised its position in Loxo Oncology by 2.1% in the fourth quarter. State Street Corp now owns 214,321 shares of the biopharmaceutical company’s stock worth $6,882,000 after buying an additional 4,360 shares during the period. Teachers Advisors LLC raised its position in Loxo Oncology by 4.3% in the fourth quarter. Teachers Advisors LLC now owns 22,139 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 905 shares during the period. Candriam Luxembourg S.C.A. raised its position in Loxo Oncology by 28.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 103,000 shares of the biopharmaceutical company’s stock worth $4,334,000 after buying an additional 23,000 shares during the period. Nationwide Fund Advisors raised its position in Loxo Oncology by 31.9% in the first quarter. Nationwide Fund Advisors now owns 27,434 shares of the biopharmaceutical company’s stock worth $1,154,000 after buying an additional 6,632 shares during the period. Finally, Wells Fargo & Company MN raised its position in Loxo Oncology by 33.3% in the first quarter. Wells Fargo & Company MN now owns 15,503 shares of the biopharmaceutical company’s stock worth $653,000 after buying an additional 3,875 shares during the period.

Shares of Loxo Oncology, Inc. (NASDAQ LOXO) opened at 74.06 on Tuesday. The firm has a 50-day moving average price of $74.99 and a 200-day moving average price of $55.31. The firm’s market capitalization is $2.21 billion. Loxo Oncology, Inc. has a 1-year low of $17.14 and a 1-year high of $83.12.

Loxo Oncology (NASDAQ:LOXO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by $0.15. During the same quarter in the prior year, the firm earned ($0.77) EPS. On average, analysts forecast that Loxo Oncology, Inc. will post ($4.34) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/lmr-partners-llp-purchases-shares-of-59551-loxo-oncology-inc-loxo/1490446.html.

LOXO has been the subject of a number of recent research reports. Cowen and Company reiterated an “outperform” rating on shares of Loxo Oncology in a report on Monday, June 5th. BidaskClub lowered Loxo Oncology from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Citigroup Inc. upgraded Loxo Oncology from a “neutral” rating to a “buy” rating and set a $86.00 target price for the company in a report on Monday, June 5th. Zacks Investment Research lowered Loxo Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, May 9th. Finally, BTIG Research reiterated a “buy” rating and issued a $75.00 target price on shares of Loxo Oncology in a report on Tuesday, June 6th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $79.67.

In other Loxo Oncology news, Director Keith T. Flaherty sold 7,250 shares of the company’s stock in a transaction dated Monday, May 22nd. The shares were sold at an average price of $45.09, for a total value of $326,902.50. Following the completion of the transaction, the director now directly owns 27,141 shares of the company’s stock, valued at approximately $1,223,787.69. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 27.80% of the company’s stock.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology, Inc. (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.